CERT Certara

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

  • Morgan Stanley 22nd Annual Global Healthcare Conference

    Date and Time: Wednesday, September 4 at 4:05 p.m. ET
  • Baird Global Healthcare Conference

    Date and Time: Wednesday, September 11 at 10:15 a.m. ET

Live webcasts for each of the conferences will be available on Certara’s investor relations website at and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Investor Relations Contact:

David Deuchler

Gilmartin Group

Media Contact:

Alyssa Horowitz



EN
21/08/2024

Underlying

CERTCertara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE
Free
CERT CERTARA

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing St...

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times RADNOR, Pa., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001. IG...

September 18, 2024 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTSH Tile Shop Holdi...
SPWH Sportmans Wareh... ... (+17)

InsiderInsights.com Daily Ratings Report: September 10, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
PAYC PAYCOM SOFTWARE INC.
MTDR MATADOR RESOURCES COMPANY
CRWS CROWN CRAFTS INC.
CHCT COMMUNITY HEALTHCARE TRUST INCORPORATED
TCPC BLACKROCK TCP CAPITAL CORP.
ONEW ONEWATER MARINE
ADV ADVANTAGE SOLUTIONS INC (A)
CERT CERTARA
OLO OLO
INBX INHIBRX
TDUP INC.
MRNA THREDUP INC.
MODERNA
INC.
09/11/24 September 11, 2024 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare ConferenceDate and Time: Wednesday, September 4 at 4:05 p.m. ET Baird Global Healthcare ConferenceDate and Time: Wednesday, September 11 at 10:15 a.m. ET Live webcasts for each of the conferences will be available on Certara’s investor relations website at and will...

August 21, 2024 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Launches Phoenix™ Version 8.5 Drug Development Software

Certara Launches Phoenix™ Version 8.5 Drug Development Software RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical industry's gold standard in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. The Phoenix Platform is used by more than 75 of the top 100 pharmaceutical companies worldwide. Eleven regulatory agencies, including the U.S. FDA, Japan PMDA, and China NMPA, rely on Phoenix to evalu...

August 15, 2024 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Reports Second Quarter 2024 Financial Results

Certara Reports Second Quarter 2024 Financial Results Reiterates Full Year 2024 Financial Guidance RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2024. Second Quarter Highlights: Revenue was $93.3 million, compared to $90.5 million in the second quarter of 2023, representing growth of 3%. Software revenue was $38.2 million, compared to $33.7 million in the second quarter of 2023, representing growth of 13%.Services revenue was $55...

August 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch